Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
06 2023
Historique:
medline: 10 5 2023
pubmed: 9 3 2023
entrez: 8 3 2023
Statut: ppublish

Résumé

Hallmarks of primary hyperoxaluria type 3 are nephrolithiasis and hyperoxaluria. However, little is known about factors influencing stone formation in this disease. We characterized stone events and examined associations with urine parameters and kidney function in a primary hyperoxaluria type 3 population. We retrospectively analyzed clinical, and laboratory data of 70 primary hyperoxaluria type 3 patients enrolled in the Rare Kidney Stone Consortium Primary Hyperoxaluria Registry. Kidney stones occurred in 65/70 primary hyperoxaluria type 3 patients (93%). Among the 49 patients with imaging available, the median (IQR) number of stones was 4 (2, 5), with largest stone 7 mm (4, 10) at first imaging. Clinical stone events occurred in 62/70 (89%) with median number of events per patient 3 (2, 6; range 1-49). Age at first stone event was 3 years (0.99, 8.7). Lifetime stone event rate was 0.19 events/year (0.12, 0.38) during follow-up of 10.7 (4.2, 26.3) years. Among 326 total clinical stone events, 139 (42.6%) required surgical intervention. High stone event rates persisted for most patients through the sixth decade of life. Analysis was available for 55 stones: pure calcium oxalate accounted for 69%, with mixed calcium oxalate and phosphate in 22%. Higher calcium oxalate supersaturation was associated with increased lifetime stone event rate after adjusting for age at first event (IRR [95%CI] 1.23 [1.16, 1.32]; Stones impose a lifelong burden on primary hyperoxaluria type 3 patients. Reducing urinary calcium oxalate supersaturation may reduce event frequency and surgical intervention.

Identifiants

pubmed: 36888927
doi: 10.1097/JU.0000000000003400
doi:

Substances chimiques

Calcium Oxalate 2612HC57YE

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1141-1150

Subventions

Organisme : NIDDK NIH HHS
ID : U54 DK083908
Pays : United States
Organisme : NCATS NIH HHS
ID : R21 TR003174
Pays : United States

Auteurs

Muhammad G Arnous (MG)

Divison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.

Lisa Vaughan (L)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Ramila A Mehta (RA)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

Phillip J Schulte (PJ)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

John C Lieske (JC)

Divison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Dawn S Milliner (DS)

Divison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Division of Pediatric Nephrology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH